Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 2/20 | 0.47 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.47 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 10/20 | 0.44 |
| ▸ | MAPK3 | P27361 | 7/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10320722 | 0.91 | ROCK2 (0.56) | DYRK1AROCK2S1PR3S1PR1MAPK1 | |
| SCHEMBL10322148 | 0.89 | DYRK1A (0.51) | DYRK1ADYRK1BROCK2S1PR3MAPK1 | |
| SCHEMBL10324847 | 0.89 | DYRK1A (0.51) | DYRK1ADYRK1BROCK2S1PR3MAPK1 | |
| SCHEMBL10318762 | 0.87 | TAS1R3 (0.50) | DYRK1ADYRK1BROCK2MAPK1ROCK1 | |
| SCHEMBL10320709 | 0.87 | TAS1R3 (0.50) | DYRK1ADYRK1BROCK2MAPK1ROCK1 | |
| SCHEMBL10317811 | 0.87 | TAS1R3 (0.50) | DYRK1ADYRK1BROCK2MAPK1ROCK1 | |
| SCHEMBL10322647 | 0.87 | DYRK1A (0.48) | DYRK1ADYRK1BROCK2S1PR3S1PR1 | |
| Trifluoroacetic Acid SCHEMBL10319963 | 0.81 | TAS1R3 (0.45) | DYRK1ADYRK1BROCK2MAPK1ROCK1 | |
| Trifluoroacetic Acid SCHEMBL10321622 | 0.81 | TAS1R3 (0.45) | DYRK1ADYRK1BROCK2MAPK1ROCK1 | |
| SCHEMBL22100796 | 0.81 | ROCK2 (0.45) | DYRK1ADYRK1BROCK2S1PR3S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120184562-A1 | 1,6- AND 1,8-NAPHTHYRIDINES | LUK KIN-CHUN (US) | 2012-07-19 | — | — | US | claimed |
| US-20120184562-A1 | 1,6- AND 1,8-NAPHTHYRIDINES | LUK KIN-CHUN (US) | 2012-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184562-A1 | 1,6- AND 1,8-NAPHTHYRIDINES | PSEN1, BRCA1, PSEN2 | DYRK1A 1366/4885DYRK1B 2109/4885ROCK2 2638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.